Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Net Margin (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Net Margin for 16 consecutive years, with 4.93% as the latest value for Q4 2025.

  • On a quarterly basis, Net Margin rose 5840.0% to 4.93% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.8%, a 3604.0% increase, with the full-year FY2025 number at 0.8%, up 3886.0% from a year prior.
  • Net Margin was 4.93% for Q4 2025 at Anika Therapeutics, down from 3.04% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 17.12% in Q2 2021 to a low of 532.91% in Q4 2023.
  • A 5-year average of 47.74% and a median of 7.58% in 2022 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: plummeted -31475bps in 2023, then surged 46958bps in 2024.
  • Anika Therapeutics' Net Margin stood at 16.17% in 2021, then crashed by -1249bps to 218.16% in 2022, then tumbled by -144bps to 532.91% in 2023, then skyrocketed by 88bps to 63.33% in 2024, then soared by 92bps to 4.93% in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Net Margin are 4.93% (Q4 2025), 3.04% (Q3 2025), and 2.4% (Q2 2025).